Krause K J
J Insur Med. 2001;33(1):4-11.
C-reactive protein (CRP) is one of a number of substances termed "acute phase reactants," biologic substances that appear in the circulation when an active inflammatory process occurs. Although traditionally used to monitor or detect major infectious or inflammatory conditions, elevations of CRP levels within the conventional range of "normals" has been intensively studied as a marker for coronary disease and risk of future coronary events. Sensitive assays that can be performed on a high-volume, commercial basis are now available. CRP appears to be a valuable marker for the prediction of future events in individuals who have known coronary artery disease. CRP has been proposed as a coronary disease-screening test for healthy individuals; however, available data suggest that use of CRP in this context may be premature. This paper reviews published research concerning CRP and the prediction of cardiovascular and total mortality risk, then outlines the current "state of the art" for the application of CRP to the risk assessment process.
C反应蛋白(CRP)是被称为“急性期反应物”的多种物质之一,这些生物物质在发生活跃的炎症过程时出现在循环系统中。尽管传统上用于监测或检测主要的感染或炎症状况,但在“正常”的常规范围内CRP水平的升高已作为冠心病和未来冠心病事件风险的标志物进行了深入研究。现在已有可在高容量商业基础上进行的灵敏检测方法。CRP似乎是预测已知患有冠状动脉疾病个体未来事件的有价值标志物。CRP已被提议作为健康个体的冠心病筛查测试;然而,现有数据表明在此背景下使用CRP可能为时过早。本文回顾了已发表的关于CRP以及心血管和全因死亡风险预测的研究,然后概述了目前将CRP应用于风险评估过程的“技术现状”。